Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 12/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 12/20 | 0.73 |
| ▸ | POLB | P06746 | 7/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 0.73 |
| ▸ | CCR6 | P51684 | 3/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.73 |
| ▸ | LMNA | P02545 | 3/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.73 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.73 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.69 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.69 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.69 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.69 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.69 |
| ▸ | RAB9A | P51151 | 4/20 | 0.59 |
| ▸ | NPC1 | O15118 | 6/20 | 0.59 |
| ▸ | MAPT | P10636 | 6/20 | 0.55 |
| ▸ | HTT | P42858 | 5/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14560563 | 0.95 | MEN1 (0.76) | MEN1KMT2APOLBNPSR1CCR6 | |
| SCHEMBL10314966 | 0.86 | HDAC3 (0.77) | MEN1KMT2APOLBNPSR1CCR6 | |
| SCHEMBL11938816 | 0.86 | MEN1 (0.53) | MEN1KMT2APOLBNPSR1CCR6 | |
| SCHEMBL12009445 | 0.86 | MEN1 (0.53) | MEN1KMT2APOLBNPSR1CCR6 | |
| SCHEMBL5110975 | 0.85 | HDAC3 (0.78) | MEN1KMT2APOLBNPSR1CCR6 | |
| SCHEMBL10018568 | 0.84 | MEN1 (0.68) | MEN1KMT2APOLBNPSR1CCR6 | |
| SCHEMBL16213194 | 0.84 | MEN1 (1.00) | MEN1KMT2APOLBNPSR1CCR6 | |
| SCHEMBL9504085 | 0.84 | MEN1 (0.71) | MEN1KMT2APOLBNPSR1CCR6 | |
| SCHEMBL4100327 | 0.83 | POLB (0.52) | MEN1KMT2APOLBNPSR1CCR6 | |
| SCHEMBL5114261 | 0.83 | HDAC3 (0.77) | MEN1KMT2APOLBNPSR1CCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215815-A1 | Neurotrophin antagonist compositions | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-08-27 | — | — | US | claimed |
| EP-0930883-B1 | NEUROTROPHIN ANTAGONISTS FOR THE TREATMENT OF EPILEPSY, ALZHEIMER'S DISEASE AND PAIN | ALLELIX BIOPHARMA (CA) | 2006-01-11 | — | — | EP | claimed |
| US-20050250807-A1 | Neurotrophin antagonist compositions | TEHIM ASHOK | 2005-11-10 | — | — | US | claimed |
| US-20020169182-A1 | Neurotrophin antagonist compositions | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 2002-11-14 | — | — | US | claimed |
| EP-0930883-A1 | NEUROTROPHIN ANTAGONIST COMPOSITIONS | Allelix Biopharmaceuticals Inc. (CA) | 1999-07-28 | — | — | EP | claimed |
| WO-1998017278-A1 | NEUROTROPHIN ANTAGONIST COMPOSITIONS | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1998-04-30 | — | — | WO | claimed |
| US-20090215815-A1 | Neurotrophin antagonist compositions | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-08-27 | — | — | US | disclosed |
| US-20080287484-A1 | Neurotrophin antagonist compositions | TEHIM ASHOK | 2008-11-20 | — | — | US | disclosed |
| US-7291629-B2 | Neurotrophin antagonist compositions | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-11-06 | — | — | US | disclosed |
| EP-0930883-B1 | NEUROTROPHIN ANTAGONISTS FOR THE TREATMENT OF EPILEPSY, ALZHEIMER'S DISEASE AND PAIN | ALLELIX BIOPHARMA (CA) | 2006-01-11 | — | — | EP | disclosed |
| US-20050250807-A1 | Neurotrophin antagonist compositions | TEHIM ASHOK | 2005-11-10 | — | — | US | disclosed |
| US-20020169182-A1 | Neurotrophin antagonist compositions | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 2002-11-14 | — | — | US | disclosed |
| EP-0930883-A1 | NEUROTROPHIN ANTAGONIST COMPOSITIONS | Allelix Biopharmaceuticals Inc. (CA) | 1999-07-28 | — | — | EP | disclosed |
| WO-1998017278-A1 | NEUROTROPHIN ANTAGONIST COMPOSITIONS | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1998-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215815-A1 | Neurotrophin antagonist compositions | NGF, NTRK2, BDNF | MEN1 4269/4885KMT2A 3457/4885POLB 2700/4885 |
| US-20050250807-A1 | Neurotrophin antagonist compositions | NGF, NTRK2, BDNF | MEN1 4175/4885KMT2A 3637/4885POLB 2609/4885 |
| US-20020169182-A1 | Neurotrophin antagonist compositions | NTRK2, NGF, BDNF | MEN1 4752/4885KMT2A 3113/4885POLB 3133/4885 |
| US-20080287484-A1 | Neurotrophin antagonist compositions | NGF, NTRK2, BDNF | MEN1 4146/4885KMT2A 3617/4885POLB 2702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.